All AI training jobs

Mercor · Finance & specialist

Payer & Market Access Expert — Gross-to-Net & Formulary Strategy - review AI outputs in your specialty

Listed on Mercor as “Payer & Market Access Expert - Gross-to-Net & Formulary Strategy

$175-$200/hrRemoteContractPaid in USD
ShareWhatsAppTelegramEmail

What this actually is

You bring your specialist expertise to AI evaluation. The shape of the work varies but the pattern is the same: review outputs, rate quality, write prompts, flag errors. The platform title (Payer & Market Access Expert - Gross-to-Net & Formulary Strategy) reflects the rate band and the expertise required, not the day-to-day work.

Advertisement

Can you do this on your visa?

F-2 / F-4 / F-5 / F-6: open. E-1 to E-7: needs concurrent-employment permit. D-2 / D-4 students: S-3 permit, 20 hr/week cap. D-10 / D-8: case by case.

Korean tax on USD income

First 5 years in Korea: foreign-source income only taxed if remitted into Korea. After year 5: worldwide income. Full tax guide.

Original posting from Mercor

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work - creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a payer / market access expert for a paid pilot, with the potential to continue as the work scales.

Responsibilities

  • Create and critique rubrics that analyze commercial drugs and drug-development programs
  • Set and pressure-test gross-to-net and formulary-tier assumptions by drug class
  • Judge whether coverage, rebating, and tiering assumptions reflect how payers actually behave
  • Apply this across the pilot's set of drugs and drug classes

Requirements

  • US-based payer / market access professional
  • Familiarity with biotech/pharma development programs
  • Hands-on with gross-to-net, rebates, and formulary tiering by drug class
  • 5+ years in market access, pricing & reimbursement, or managed markets

Engagement Details

  • Duration: Approximately 10-20 hours over a 1-2 week pilot
  • Remote - US-based

Why Participate

  • Help improve expert AI evaluation of drugs and drug-development programs
  • Recurring engagement for strong contributors

Quoted from Mercor’s public listing on 2026-09-08. We don’t edit platform copy; honest framing is in the title and the “what this actually is” block above.

Apply on Mercor